Table of Contents
ISRN Hepatology
Volume 2013 (2013), Article ID 412317, 9 pages
http://dx.doi.org/10.1155/2013/412317
Clinical Study

Serum Levels of Interleukin-6 and Interleukin-10 as Biomarkers for Hepatocellular Carcinoma in Egyptian Patients

1Biochemistry Department, Faculty of Pharmacy, October University for Modern Sciences and Arts (MSA), Giza 11787, Egypt
2Biology Department, Faculty of Dentistry, October University for Modern Sciences and Arts (MSA), Giza 11787, Egypt
3Biochemsitry Department, National Hepatology and Tropical Medicine Research Institute, Fom El-Khalig, Cairo 11796, Egypt
4Faculty of Medicine, Ain Shams University, Cairo, Egypt

Received 30 June 2013; Accepted 12 August 2013

Academic Editors: D. Capone, A. Castiella, J. Inoue, B. Radosevic-Stasic, and Y. Yano

Copyright © 2013 Mohamed S. Othman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. P. Michielsen, S. M. Francque, and J. L. van Dongen, “Viral hepatitis and hepatocellular carcinoma,” World Journal of Surgical Oncology, vol. 3, article 27, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Castello, S. Costantini, and S. Scala, “Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment,” Journal of Translational Medicine, vol. 8, article 109, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. P. P. Michielsen, S. M. Francque, and J. L. van Dongen, “Viral hepatitis and hepatocellular carcinoma,” World Journal of Surgical Oncology, vol. 3, article 27, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Rahman El-Zayadi, H. Abaza, S. Shawky, M. K. Mohamed, O. E. Selim, and H. M. Badran, “Prevalence and epidemiological features of hepatocellular carcinoma in Egypt—a single center experience,” Hepatology Research, vol. 19, no. 2, pp. 170–179, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. S. M. Attalla, S. M. El-Azab, A. A. El-Bakary et al., “Is aflatoxin B1 a common risk factor for hepatocellular carcinoma?” Mansoura Journal of Forensic Medicine and Clinical Toxicology, vol. 17, no. 2, pp. 15–24, 2009. View at Google Scholar
  6. W. A. Anwar, H. M. Khaled, H. A. Amra, H. El-Nezami, and C. A. Loffredo, “Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention,” Mutation Research, vol. 659, no. 1-2, pp. 176–184, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. N. I. Zakhary, M. M. El-Merzabani, N. M. El-Sawi, S. M. Saleh, M. M. Moneer, and R. H. Mohamad, “Impact of different biochemical markers in serum of patients with benign and malignant liver diseases,” Journal of Advanced Research, vol. 2, no. 1, pp. 49–55, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. M. Llovet, A. Burroughs, and J. Bruix, “Hepatocellular carcinoma,” The Lancet, vol. 362, no. 9399, pp. 1907–1917, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. J. A. Marrero, “Hepatocellular Carcinoma,” in Hepatology: A Textbook of Liver Disease, D. Zakim and T. D. Boyer, Eds., pp. 1005–1030, WB Saunders, Philadelphia, Pa, USA, 6th edition, 2012. View at Google Scholar
  10. E. M. Lehman, A. S. Soliman, K. Ismail et al., “Patterns of hepatocellular carcinoma incidence in Egypt from a population-based cancer registry,” Hepatology Research, vol. 38, no. 5, pp. 465–473, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Y. Kim, J. W. Kim, R. Kuromatsu, S. H. Ahn, T. Torimura, and M. Sherman, “Controversies in surveillance and early diagnosis of hepatocellular carcinoma,” Oncology, vol. 81, no. 1, pp. 56–60, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. W. M. Korn, “Moving toward an understanding of the metastatic process in hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 7, no. 6, pp. 777–778, 2001. View at Google Scholar · View at Scopus
  13. A.-R. N. Zekri, M. S. El-din Ashour, A. Hassan, H. M. A. El-Din, A. M. R. El-Shehaby, and M. A. Abu-Shady, “Cytokine profile in Egyptian hepatitis C virus genotype-4 in relation to liver disease progression,” World Journal of Gastroenterology, vol. 11, no. 42, pp. 6624–6630, 2005. View at Google Scholar · View at Scopus
  14. G.-Y. Chau, C.-W. Wu, W.-Y. Lui et al., “Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma,” Annals of Surgery, vol. 231, no. 4, pp. 552–558, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Wieckowska, B. G. Papouchado, Z. Li, R. Lopez, N. N. Zein, and A. E. Feldstein, “Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis,” American Journal of Gastroenterology, vol. 103, no. 6, pp. 1372–1379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. W. E. Naugler and M. Karin, “The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer,” Trends in Molecular Medicine, vol. 14, no. 3, pp. 109–119, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. C.-Y. Hsia, T.-I. Huo, S.-Y. Chiang et al., “Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma,” European Journal of Surgical Oncology, vol. 33, no. 2, pp. 208–212, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Taylor, J. Verhagen, K. Blaser, M. Akdis, and C. A. Akdis, “Mechanisms of immune suppression by interleukin-10 and transforming growth factor-β: the role of T regulatory cells,” Immunology, vol. 117, no. 4, pp. 433–442, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Kuo, Q.-L. Choo, H. J. Alter et al., “An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis,” Science, vol. 244, no. 4902, pp. 362–364, 1989. View at Google Scholar · View at Scopus
  20. A.-R. N. Zekri, A. A. Bahnassy, S. M. Shaarawy et al., “Hepatitis C virus genotyping in relation to neu-oncoprotein overexpression and the development of hepatocellular carcinoma,” Journal of Medical Microbiology, vol. 49, no. 1, pp. 89–95, 2000. View at Google Scholar · View at Scopus
  21. A. Voller, A. Bartlett, and D. E. Bidwell, “Enzyme immunoassays with special reference to ELISA techniqies,” Journal of Clinical Pathology, vol. 31, no. 6, pp. 507–520, 1978. View at Google Scholar · View at Scopus
  22. L.-X. Qin and Z.-Y. Tang, “The prognostic molecular markers in hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 8, no. 3, pp. 385–392, 2002. View at Google Scholar · View at Scopus
  23. H. T. Mollay and K. A. Evelyn, “Determination of bilirubin with photoelectric colorimeter,” The Journal of Biological Chemistry, vol. 119, pp. 481–485, 1937. View at Google Scholar
  24. R. J. Henry, N. Chiamori, O. J. Gloub, and S. Berkman, “Revised spectrophotometric methods for the determination of glutamic-oxalacetic transaminase, glutamic-pyruvic transaminase, and lactic acid dehydrogenase,” American journal of clinical pathology, vol. 34, pp. 381–398, 1960. View at Google Scholar · View at Scopus
  25. A. E. Pinnell and B. E. Northam, “New automated dye binding method for serum albumin determination with bromcresol purple,” Clinical Chemistry, vol. 24, no. 1, pp. 80–86, 1978. View at Google Scholar · View at Scopus
  26. A. J. Quick, “Determination of prothrombin,” American Journal of Clinical Pathology, vol. 246, pp. 517–519, 1963. View at Google Scholar
  27. W. Groner and E. Epstein, “Counting and sizing of blood cells using light scattering,” in Advances in Hematological Methods, J. M. England and O. W. Van Assendelft, Eds., pp. 567–568, CRC Press, Boca Raton, Fla, USA, 1982. View at Google Scholar
  28. S. Bolton and C. Bon, Pharmaceutical Statistics: Practical and Clinical Applicationsedition, Marcel Dekker, New York, NY, USA, 4th edition, 2003.
  29. E. S. Bialecki and A. M. Di Bisceglie, “Diagnosis of hepatocellular carcinoma,” HPB, vol. 7, no. 1, pp. 26–34, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. Q. Wang, W. Luan, G. A. Villanueva et al., “Clinical prognostic variables in young patients (under 40 years) with hepatitis B virus-associated hepatocellular carcinoma,” Journal of Digestive Diseases, vol. 13, no. 4, pp. 214–218, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Budhu and W. W. Xin, “The role of cytokines in hepatocellular carcinoma,” Journal of Leukocyte Biology, vol. 80, no. 6, pp. 1197–1213, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Porta, M. De Amici, S. Quaglini et al., “Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma,” Annals of Oncology, vol. 19, no. 2, pp. 353–358, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Zhou, J.-A. Rui, S.-B. Wang, S.-G. Chen, and Q. Qu, “The significance of serum AFP cut-off values, 20 and 400 ng/mL in curatively resected patients with hepatocellular carcinoma and cirrhosis might be of difference,” Hepato-Gastroenterology, vol. 59, no. 115, pp. 840–843, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. S. B. Paul, M. S. Gulati, V. Sreenivas et al., “Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein,” Oncology, vol. 72, no. 1, pp. 117–123, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Ishii, H. Gama, N. Chida et al., “Simultaneous measurements of serum α-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma,” American Journal of Gastroenterology, vol. 95, no. 4, pp. 1036–1040, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Abdel-Haleem, S. El Kateb, N. Gohar, and E. Hamdy, “Evaluation of the diagnostic and prognostic value of AFP, PIVKA-II, VEGF and TGF-β1 in the diagnosis and follow up of patients with hepatocellular carcinoma,” Arab Journal Gastroenterology, vol. 8, no. 3, pp. 84–89, 2007. View at Google Scholar
  37. M. E. El-Houseini, M. S. Mohammed, W. M. Elshemey, T. D. Hussein, O. S. Desouky, and A. A. Elsayed, “Enhanced detection of hepatocellular carcinoma,” Cancer Control, vol. 12, no. 4, pp. 248–253, 2005. View at Google Scholar · View at Scopus
  38. M. Abdel-Wahab, M. Mostafa, M. Sabry, M. El-Farrash, and T. Yousef, “Aflatoxins as a risk factor for hepatocellular carcinoma in Egypt, Mansoura Gastroenterology Center Study,” Hepato-Gastroenterology, vol. 55, no. 86-87, pp. 1754–1759, 2008. View at Google Scholar · View at Scopus
  39. L. Zhou, J. Liu, and F. Luo, “Serum tumor markers for detection of hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 12, no. 8, pp. 1175–1181, 2006. View at Google Scholar · View at Scopus
  40. E. N. Debruyne and J. R. Delanghe, “Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications,” Clinica Chimica Acta, vol. 395, no. 1-2, pp. 19–26, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Martin and Z. Herceg, “From hepatitis to hepatocellular carcinoma: a proposed model for cross-talk between inflammation and epigenetic mechanisms,” Genome Medicine, vol. 4, no. 1, article 8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Malaguarnera, I. Di Fazio, A. Laurino, M. A. Romeo, I. Giugno, and B. A. Trovato, “Role of the interleukin 6 in hepatocellular carcinoma,” Bulletin du Cancer, vol. 83, no. 5, pp. 379–384, 1996. View at Google Scholar · View at Scopus
  43. S. Maurizio, G. Lydia, D. Fabio et al., “Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 12, no. 16, pp. 2563–2568, 2006. View at Google Scholar · View at Scopus
  44. H. Ataseven, I. H. Bahcecioglu, N. Kuzu et al., “The levels of ghrelin, leptin, TNF-α, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection,” Mediators of Inflammation, vol. 2006, no. 4, Article ID 78380, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. M. G. Tovey, J. Gugenheim, J. Guymarho et al., “Genes for interleukin-1, interleukin-6, and tumor necrosis factor are expressed at markedly reduced levels in the livers of patients with severe liver disease,” Autoimmunity, vol. 10, no. 4, pp. 297–310, 1991. View at Google Scholar · View at Scopus
  46. H. A. Metwaly, M. M. H. Al-Gayyar, S. Eletreby, M. A. Ebrahim, and M. M. El-Shishtawy, “Relevance of serum levels of interleukin-6 and syndecan-1 in patients with hepatocellular carcinoma,” Scientia Pharmaceutica, vol. 80, no. 1, pp. 179–188, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. X. Jin, T. A. Zimmers, E. A. Perez, R. H. Pierce, Z. Zhang, and L. G. Koniaris, “Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair,” Hepatology, vol. 43, no. 3, pp. 474–484, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. V. W.-S. Wong, J. Yu, A. S.-L. Cheng et al., “High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B,” International Journal of Cancer, vol. 124, no. 12, pp. 2766–2770, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Zhu and G. V. Paddock, “Expression of the hepatocyte growth factor-like protein gene in human hepatocellular carcinoma and interleukin-6-induced increased expression in hepatoma cells,” Biochimica et Biophysica Acta, vol. 1449, no. 1, pp. 63–72, 1999. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Zou, H. Zhang, Q. Li et al., “Heme oxygenase-1: a molecular brake on hepatocellular carcinoma cell migration,” Carcinogenesis, vol. 32, no. 12, Article ID bgr225, pp. 1840–1848, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Liu, P. K. Li, C. Li, and J. Lin, “Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells,” The Journal of Biological Chemistry, vol. 285, no. 35, pp. 27429–27439, 2010. View at Google Scholar
  52. K. Kovalovich, W. Li, R. DeAngelis, L. E. Greenbaum, G. Ciliberto, and R. Taub, “Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL,” The Journal of Biological Chemistry, vol. 276, no. 28, pp. 26605–26613, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. V. Wallenius, K. Wallenius, M. Hisaoka et al., “Retarded liver growth in interleukin-6-deficient and tumor necrosis factor receptor-1-deficient mice,” Endocrinology, vol. 142, no. 7, pp. 2953–2960, 2001. View at Publisher · View at Google Scholar · View at Scopus
  54. E. Hattori, K. Okumoto, T. Adachi et al., “Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma,” Hepatology Research, vol. 27, no. 4, pp. 308–313, 2003. View at Google Scholar · View at Scopus
  55. O. Delpuech, D. Buffello-Le Guillou, E. Rubinstein, C. Féray, and M.-A. Petit, “The hepatitis C virus (HCV) induces a long-term increase of interleukin-10 production by human CD4+ T cells (H9),” European Cytokine Network, vol. 12, no. 1, pp. 69–77, 2001. View at Google Scholar · View at Scopus
  56. S. Beckebaum, X. Zhang, X. Chen et al., “Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets,” Clinical Cancer Research, vol. 10, no. 21, pp. 7260–7269, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. G. A. Gastl, J. S. Abrams, D. M. Nanus et al., “Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression,” International Journal of Cancer, vol. 55, no. 1, pp. 96–101, 1993. View at Google Scholar · View at Scopus